Undisclosed Cbl-b inhibitor / Simcere, Sparkle Therap - LARVOL DELTA

An oral Cbl-b inhibitor with sustained T cell activation demonstrated robust anti-tumor efficacy along with enhanced infiltration and activation of functional T cells (AACR 2024) - "In conclusion, our Cbl-b inhibitor exhibited a favorable PK profile in multi-preclinical animals. The sustained T cell activation in vitro was identified and robust anti-tumor growth in vivo was demonstrated with optimized dosing frequency."

Clinical • Hematological Malignancies • Lymphoma • Oncology • CD8 • GZMB • IFNG • TGFB1

Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody (AACR 2023) - "In conclusion, our selective Cbl-b inhibitors demonstrated robust immune activation and anti-tumor activity in vitro and in vivo and showed synergistic activities with immune checkpoint inhibitors, such as anti-PD(L)1. Currently, one of our leading molecules is in IND enabling studies."

Combination therapy • Hematological Malignancies • Lymphoma • Oncology • IL2 • VAV1

Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies (AACR 2023) - "preclinical data provided evidence of CBL-B inhibitors to enhance key parameters associated with T/NK cell activation and reduce susceptibility to immune suppression. Our results suggest the combination strategy of cell therapy and immune regulating small/large molecule therapy might achieve better anti-tumor efficacy in both hematological and solid tumors."

IO biomarker • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CD8 • IL15 • NKG2D • TGFB1